Patents by Inventor Hengli Yuan

Hengli Yuan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereof
    Patent number: 11771773
    Abstract: Disclosed are a GLP-1-mimicking pharmaceutical composition for treating type 2 diabetes and a preparation method thereof, wherein the pharmaceutical composition contains polyethylene glycol loxenatide, a physiologically acceptable buffer with the pH of 3.0-7.0, and pharmaceutically acceptable excipients. The pharmaceutical composition has good drug stability.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: October 3, 2023
    Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Inventors: Li Dong, Ge Wang, Di Hu, Yundong Sun, Hengli Yuan
  • PHARMACEUTICAL PREPARATION CONTAINING POLYETHYLENE GYLCOL LOXENATIDE AND PREPARATION METHOD THEREOF
    Publication number: 20220088205
    Abstract: Disclosed are a GLP-1-mimicking pharmaceutical composition for treating type 2 diabetes and a preparation method thereof, wherein the pharmaceutical composition contains polyethylene glycol loxenatide, a physiologically acceptable buffer with the pH of 3.0-7.0, and pharmaceutically acceptable excipients. The pharmaceutical composition has good drug stability.
    Type: Application
    Filed: October 16, 2017
    Publication date: March 24, 2022
    Inventors: Li Dong, Ge Wang, Di Hu, Yundong Sun, Hengli Yuan
  • Crystal form of a potassium-competitive acid blocker and preparation method thereof
    Patent number: 10538506
    Abstract: The present invention relates to a crystal form of a potassium-competitive acid blocker, that is, 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrole-3-yl]-N-methyl methylamine fumaric acid salt (which is briefly referred to as a formula I) and a preparation method thereof. An X-ray powder diffraction characteristic peak thereof is shown in FIG. 1. The crystal form that is represented by formula I, provided in the present invention, is stable, reproducible, and is suitable for drug development.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: January 21, 2020
    Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Inventors: Hongwei Tang, Changan Sun, Ruijun Wang, Hengli Yuan
  • CRYSTAL FORM OF A POTASSIUM-COMPETITIVE ACID BLOCKER AND PREPARATION METHOD THEREOF
    Publication number: 20180282300
    Abstract: The present invention relates to a crystal form of a potassium-competitive acid blocker, that is, 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrole-3-yl]-N-methyl methylamine fumaric acid salt (which is briefly referred to as a formula I) and a preparation method thereof. An X-ray powder diffraction characteristic peak thereof is shown in FIG. 1. The crystal form that is represented by formula I, provided in the present invention, is stable, reproducible, and is suitable for drug development.
    Type: Application
    Filed: November 9, 2015
    Publication date: October 4, 2018
    Applicants: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Inventors: Hongwei TANG, Changan SUN, Ruijun WANG, Hengli YUAN
  • Human insulin analogue and acylated derivative thereof
    Patent number: 9458219
    Abstract: The present invention provides a human insulin analog, an acylated derivative thereof and a physiologically acceptable salt. The present invention further provides a preparation method for the insulin analog and an application of the insulin analog as a therapeutic agent, and particularly as a diabetes mellitus therapeutic agent.
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: October 4, 2016
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Piaoyang Sun, Lianshan Zhang, Jiajian Liu, Jijun Yuan, Chunqian Fang, Changan Sun, Hengli Yuan, Yali Wang
  • HUMAN INSULIN ANALOGUE AND ACYLATED DERIVATIVE THEREOF
    Publication number: 20140329745
    Abstract: The present invention provides a human insulin analogue, an acylated derivative thereof and a physiologically acceptable salt. The present invention further provides a preparation method for the insulin analogue and an application of the insulin analogue as a therapeutic agent, and particularly as a diabetes mellitus therapeutic agent.
    Type: Application
    Filed: November 22, 2012
    Publication date: November 6, 2014
    Inventors: Piaoyang Sun, Lianshan Zhang, Jiajian Liu, Jijun Yuan, Chunqian Fang, Changan Sun, Hengli Yuan, Yali Wang
  • GLP-1 analogues and their pharmaceutical salts and uses
    Patent number: 8614182
    Abstract: This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: December 24, 2013
    Assignee: Jiangsu Hansoh Pharmaceuticals Co., Ltd.
    Inventors: Yali Wang, Aifeng Lü, Changan Sun, Hengli Yuan
  • GLP-1 ANALOGUES AND THEIR PHARMACEUTICAL SALTS AND USES
    Publication number: 20120196798
    Abstract: This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity.
    Type: Application
    Filed: January 31, 2012
    Publication date: August 2, 2012
    Inventors: Yali Wang, Aifeng Lü, Changan Sun, Hengli Yuan
  • GLP-1 ANALOGUES AND THEIR PHARMACEUTICAL SALTS AND USES
    Publication number: 20120129768
    Abstract: This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity.
    Type: Application
    Filed: July 29, 2010
    Publication date: May 24, 2012
    Inventors: Yali Wang, Aifeng Lü, Changan Sun, Hengli Yuan